|Table of Contents|

Analysis of the correlation between the site of occurrence and the site of metastasis in mucosal melanoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 05
Page:
864-867
Research Field:
Publishing date:

Info

Title:
Analysis of the correlation between the site of occurrence and the site of metastasis in mucosal melanoma
Author(s):
XIANG Mei; LIANG Xianbin; ZHAO Dongli; WANG Yan; HU Shanshan; ZHANG Weizhen
The Third People's Hospital of Zhengzhou,Cancer Hospital Affiliated to Henan University,Henan Zhengzhou 450000,China.
Keywords:
mucosal; melanoma; primary site; metastasis site; gene detection
PACS:
R739.5
DOI:
10.3969/j.issn.1672-4992.2021.05.032
Abstract:
Objective:To investigate whether there is a correlation between the location of primary site and metastasis site of mucosal melanoma and the relationship between genomic characteristics and prognosis.Methods:Epidemiological investigation was carried out on 92 patients with mucous melanoma diagnosed by pathology,and the relevant factors of the primary and metastatic sites of the tumor were summarized and analyzed.Results:Among the 92 patients with mucosal melanoma,the head and neck had a high incidence of mucous melanoma,with a total of 46(50%),followed by the urogenital system in 25(27.17%) and anorectal in 21(22.83%).The most common metastatic sites of head and neck melanoma were regional lymph nodes (63.04%) and lung (23.91%).The most common metastatic sites of anorectal melanoma were regional lymph nodes (57.14%),lung (19.05%) and liver (28.57%).The most common metastatic sites of urogenital melanoma were regional lymph nodes (32.00%),lung (32.00%) and liver (20.00%).Among the 33 people who underwent genetic testing,there were 2(6.06%) had BRAF V600E mutation,1(3.03%) had CKIT mutation,and 4(12.12%) had NRAS mutation.Conclusion:Lymph node metastasis is the most common in head and neck melanoma,followed by anorectal melanoma.The proportion of lymph node metastasis in urogenital melanoma is low.Local recurrence of head and neck is often accompanied by lymph node metastasis.Gene detection and targeted therapy bring survival benefits to more patients.

References:

［1］CHANG AE，KARNELL LH，MENEK HR.The National Cancer Data Base report on cutaneous and noneutaneous melanoma：a summary of 84 836 cases from the past decade:The American College of Surgeons Commission on Cancer and the American Cancer Society［J］.Cancer,1998，83(8):1664-1678．
［2］ MARKOVIC SN,ERICKSON LA,RAO RD,et al.Malignant melanoma in the 21st century partle pidemiology risk factors screening prevention and diagnosis［J］.Mayo Clin Proc,2007,82(3):364-380.
［3］ WILKERSON BL.Malignant melanoma［J］.Plast Surg Nurs,2011,31(3):105407.
［4］ MCLAUGHLIN CC，WU XC，JEMAL A，et al.Incidence of noncutaneous melanomas in the US［J］.Cancer,2005,103(5):1000-1007.
［5］ SUN CZ,LI QL,HU ZD,et al.Treatment and prognosis in sinonasal mucosal melanoma:A retrospective analysis of 65 patients from a single cancer center［J］.Head & Neck,2014,36(5):675-681.
［6］ DAUER EH,LEWIS JE,ROHLINGER AL,et al.Sinonasal melanoma:A clinicopathologic review of 61 cases［J］.Otolaryngology Head & Neck Surgery,2008,138(3):347-352.
［7］ BISHOP KD,OLSZEWSKI AJ.Epidemiology and survival outcomes of ocular and mucosal melanomas:A population-based analysis［J］.International Journal of Cancer,2014,134(12):2961-2971.
［8］ LOMBARDI D,BOTTAZZOLI M,TURRI-ZANONI M,et al.Sinonasal mucosal melanoma:A 12-year experience of 58 cases［J］.Head & Neck,2016,38(S1):E1737-E1745.
［9］ POSTOW MA,HAMID O,CARVAJAL RD.Mucosal melanoma:pathogenesis,clinical behavior,and management［J］.Curr Oncol Rep,2012,14:441-448.
［10］ CHI Z,LI S,SHENG X,et al.Clinical presentation,histology,and prognoses of malignant melanoma in ethnic Chinese:A study of 522 consecutive cases［J］.BMC Cancer,2011,11(1):85．
［11］ KIM HS,KIM EK,JUN HJ,et al.Nesoeanrchc aurtitclaeneous malignant melanoma:a prognostic model from a retrospective multicenter study［J］.BMC Cancer,2010,10:167.
［12］ 崔传亮,李忠武,连斌,等.212例中国黏膜黑色素瘤患者的临床病理及预后分析［J］.临床肿瘤学杂志,2012,17(7):626-633. CUI CL,LI ZW,LIAN B,et al.Clinical pathological and prognostic analysis of 212 cases of mucosal melanoma in China［J］.Journal of Clinical Oncology,2012,17(7):626-633.
［13］ VERSCHRAEGEN CF,BENJAPIBAL M,SUPAK-ARAPONGKUL W,et al.Vulvar melanoma at the MD Anderson Cancer Center:25 years later［J］.Int J Gynecol Cancer,2001,11(5):359-364.
［14］CHE G,HUANG BJ,XIE ZN,et al.Trends in incidence and survival in patients with melanoma,1974-2013［J］.Am J Cancer Res,2019,9(7):1396-1414.
［15］ HOWLADER N,NOONE AM,KRAPCHO M,et al.SEER Cancer Statistics Review,1975-2016［EB/OL］.National Cancer Institute,(2018)［2019-04］.http://www.seer.cancer.gov/csr/1975_2016/results_merged/sect_16_melanoma_skin.pdf
［16］ CRONIN KA,LAKE AJ,SCOTT S,et al.Annual report to the nation on the status of cancer,part I:National cancer statistics［J］.Cancer,2018,124(13):2785-2800.
［17］ LIAN B,CUI CL,ZHOU L,et al.The natural history and patterns of metastases from mucosal melanoma:an analysis of 706 prospectively-followed patients［J］.Annals of Oncology,2016,28(4):mdw694.
［18］ SASSE AD,SASSE EC,CLARK LG,et al.Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma［J］.Cochrane Database Syst Rev,2007,1(1):CD005413.
［19］ MELETI M,VESCOVI P,MAOI WJ,et al.Primary mucosal and perioral tissues:a flow-chart for the diagnosis and some recommendations for the mangement［J］.Oral Surg Oral Med Oral Pathal Oral Radiol Eadond,2008,105(5):606-616.
［20］ PRASAD ML,PATEL SG,HUVOS AG,et al.Primary mucosal melanomn of the head and neck:a propoal for microstaging localized,stage I (lymph node-negatie) tumors［J］.Cancer,2004,100:1646-1657.
［21］ STAREK I,KORANDA P,BENES P.Sentinel lymph node biopsy:a new perspective in head and neck mucosal melanoma［J］.Melanoma Research,2006,16:423-427.
［22］ SI L,ZHANG X,XU Z,et al.Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma:an open-label,multicenter phase I study［J］.BMC Cancer,2018,18(1):520.
［23］ FELICITY NEWELL,YAN K,JAMES S,et al.Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets［J］.Nature Commucation,2019,10(1):3163.
［24］ GUO J,SI L,KONG Y,et al.Phase II,open-label,single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification［J］.Journal of Clinical Oncology,2011,29(21):2904-2909.
［25］ GUO J,CANVAJAL RD,DUMMER R,et al.Efficacy and safety of niloinib in patients with KIT-mutated metastatic or inoperable melanoma:final resuls from the global,single-arm,phase II TEAM trial［J］.Annals of Oncology,2017,28(6):1380-1387.
［26］ CARVAJAL RD,ANTONESCU CR,WOLCHOK JD,et al.KIT as a therapeutic target in metastatic melanoma［J］.JAMA,2011,305:2327-2334.
［27］ HODI FS,CORLESS CL,GIOBBIE-HURDER A,et al.Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucoal,acral,and chronically sun-damaged skin［J］.J Clin Oncol,2013,31:3182-3190.

Memo

Memo:
河南省医学科技攻关计划项目(编号：201602323)
Last Update: 2021-01-29